Bioperfectus Granted MDA Approval in Malaysia for Nucleic Acid Extraction Systems

Company news

SHANGHAI, CHINA, November 14, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”), a leading global company in the molecular diagnostics market, today announced receipt of MDA (Medical Device Authority) approval in Malaysia for Nucleic Acid Extraction Systems, including Nucleic Acid SSNP-2000B, SSNP-3000ASSNP-9600ASMPE-960 and Extraction Rapid Kit (Magnetic Bead Method).



Bioperfectus Nucleic Acid Extraction Rapid Kit can be applied to a variety of sample types such as nasopharyngeal swab, pharyngeal swab, nasal swab, serum, plasma, urine, cervical swab, urethral swab. The purified nucleic acid can be used in downstream molecular biology experiments, including in-vitro testing. As a one-stop supplier, Bioperfectus also provides different throughputs of nucleic acid extraction systems such as SSNP and SMPE series, which allows the customers to have more flexible choices based on their sample throughput


Bioperfectus nucleic acid extraction solutions, including systems and kits, could satisfy the requirements of nucleic acid purification with multiple specimen types in automatic or manual ways. The approval allows Bioperfectus to expand access to nucleic acid extraction solutions in Malaysia and offer more diagnostics solutions for local laboratories.


Click here to download MDA Registration Certification.


About Bioperfectus


Since its founding in 2010, Bioperfectus(SSE:688399) has been dedicated to providing holistic molecular diagnostic solutions specializing in emerging infectious diseases for generations and generations to come. 


We are leading the change by offering Real-Time PCR Kits, Nucleic Acid Extraction Systems, Automation Solutions, and Rapid Tests to laboratories, hospitals, institutions, and CDCs across the globe. Bioperfectus products have been distributed to more than 100 countries around the world. As one of the leading global IVD suppliers, Bioperfectus is committed to delivering excellent services and products that meet the highest international quality and safety standards. Our global presence enables us to build close relationships with our clients and leverage our expertise to support them worldwide.


To "Embrace the world with health" has always been our mission. But that's not where our mission ends. We are getting what we have learned, researched, and prepared for the subsequent emergency calls from infectious diseases and saving people's lives. For more information, please follow us on LinkedIn or visit


Media Contact:


Clinical Validation of Bioperfectus Monkeypox Virus (MPXV) Fast Real Time PCR Kit

Jiangsu BioPerfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) applied for the clinical evaluation in XYZ Laboratory (XYZ Laboratory 2009 Ranch Rd. 620 N, STE 325, Austin, TX 78732, USA), a CAP accredited CLIA certified high complexity clinical molecular diagnostic laboratory to perform and report the Bioperfectus Monkeypox Virus (MPXV) Fast Real Time PCR Kit.


The COVID-19 is Delaying the Cervical Cancer Screening

Human papillomavirus (HPV) is the primary cause of cervical cancer, which is preventable through screening and early treatment. The elimination of cervical cancer has been defined by the WHO as achieving an incidence rate below 4 cases per 100,000 women per year since 2020.


Bioperfectus Emergency Response Training for Ebola Virus Diagnostics and Testing

Bioperfectus conducted emergency training to assist frontline healthcare professionals in Uganda using Real-Time PCR diagnostic tools for early detection and control of the latest Ebola outbreak.